Swedish drug developer Karolinska Development has appointed Bruno Lucidi as chief executive officer of the wholly-owned subsidiary KDev Oncology, and portfolio companies Aprea and Akinion Pharmaceuticals.
KDev Oncology assists the clinical portfolio companies in developing cancer drugs and attractive strategic partners and co-investors.
He has previously held positions as chief executive of Idenix and chairman of Pharmasset, as well as global head of oncology for Johnson & Johnson and European head of oncology for Bristol-Myers Squibb.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze